Rheumatoid Arthritis

Condition: Rheumatoid Arthritis  |  Category: Inflammation and Immune Health  |  Reviewed by: Brian Lamkin, DO

What Is Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease in which the immune system attacks the synovial membrane lining the joints, producing inflammation (synovitis) that progressively destroys cartilage, erodes bone, and deforms joint architecture. It most commonly affects the small joints of the hands and feet symmetrically, but can involve any synovial joint and produce extra-articular manifestations affecting the cardiovascular system, lungs, eyes, and skin.

RA is driven by the loss of immune tolerance in which the immune system produces anti-citrullinated protein antibodies (anti-CCP/ACPA) and rheumatoid factor (RF) that target synovial antigens. This autoimmune activation is initiated at mucosal surfaces: the gut (through intestinal permeability and molecular mimicry), the oral cavity (through Porphyromonas gingivalis producing the citrullination enzyme PAD), and the lungs (through smoking-induced citrullination). The joint is the target of the autoimmune attack, but the trigger originates at the mucosal barrier.

Why Rheumatoid Arthritis Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

RA is not caused by the joints. The joints are the target. The cause is a mucosal immune activation at the gut, oral, or pulmonary barrier that triggers antibody production against citrullinated proteins expressed in the synovium.

The Gut-Joint Axis

Gut microbiome disruption is increasingly recognized as a central mechanism in RA pathogenesis. Prevotella copri overgrowth is consistently found in early, treatment-naive RA patients. Intestinal permeability allows bacterial antigens to cross the gut barrier and trigger immune responses through molecular mimicry, in which the immune system attacks both the bacterial antigen and structurally similar synovial proteins. Gut restoration directly addresses this upstream trigger.

Oral Microbiome and Citrullination

Porphyromonas gingivalis, the bacterium responsible for periodontitis, produces peptidylarginine deiminase (PAD), the enzyme that citrullinates proteins. Citrullinated proteins are the specific antigens that anti-CCP antibodies target. Periodontal disease is an independent risk factor for RA, and periodontal treatment has been shown to reduce RA disease activity. Oral health assessment should be a standard component of RA evaluation.

Inflammation, Nutrient Deficiency, and Immune Dysregulation

Chronic inflammation in RA depletes antioxidant reserves (glutathione, selenium, zinc), reduces vitamin D levels (which impairs T regulatory cell function), and produces an omega-6 dominant prostaglandin profile that amplifies inflammatory signaling. These nutritional deficits perpetuate the immune dysregulation that drives the disease. Chronic stress compounds this through cortisol-mediated immune imbalance favoring Th17 pro-inflammatory pathways.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The early RA patient who was never asked about gut health: Newly diagnosed seropositive RA in a 38-year-old woman. Started on methotrexate. No gut evaluation performed. Comprehensive stool analysis: Prevotella copri overgrowth, elevated calprotectin, reduced Lactobacillus diversity. Vitamin D 18, selenium low. The gut-joint axis mechanism was active and untreated. Gut restoration, vitamin D and selenium repletion, and omega-3 optimization added to methotrexate. DAS28 improved from moderate to low disease activity within 4 months.
• The RA patient with periodontal disease whose dentist and rheumatologist never communicated: Active RA on adalimumab with persistent flares. Severe periodontitis identified on dental examination. P. gingivalis confirmed. Comprehensive periodontal treatment produced measurable anti-CCP decline and reduced flare frequency. The oral source of citrullination was perpetuating the autoimmune response despite biologic therapy.
• The patient on biologics with RA remission but cardiovascular risk unaddressed: Low disease activity on tocilizumab. CRP suppressed by the biologic. But fasting insulin 14, triglyceride/HDL ratio 4.8, hs-CRP suppressed pharmacologically but metabolic inflammation persistent. RA patients have 50 to 60 percent increased cardiovascular mortality. The biologic controlled the joint disease but the metabolic cardiovascular risk was invisible and unmanaged. Comprehensive cardiovascular risk evaluation and insulin sensitization addressed the mortality risk that joint-focused treatment did not.

Treatment and Optimization Strategy

Integrated RA Management

What Most Doctors Miss

• The gut-joint axis is not evaluated: Prevotella copri overgrowth and intestinal permeability are documented drivers of RA that standard rheumatology does not assess. Gut restoration directly addresses the upstream immune trigger.
• Oral health is disconnected from RA management: P. gingivalis produces the citrullination enzyme that generates the antigens the immune system attacks. Periodontal assessment and treatment should be integrated into every RA management plan.
• Nutrient deficiencies impair immune regulation: vitamin D, selenium, zinc, and omega-3 deficiency reduce the T regulatory cell function and antioxidant capacity needed for disease control. These are modifiable factors that standard care does not proactively optimize.
• Cardiovascular risk is the leading cause of RA mortality: RA increases cardiovascular death by 50 to 60 percent. This risk is driven by chronic inflammation and is independent of joint disease activity. Comprehensive cardiovascular evaluation should be routine in every RA patient.

When to Seek Medical Care

If you experience symmetric joint pain with prolonged morning stiffness (over 60 minutes), joint swelling affecting the small joints of the hands or feet, or have been diagnosed with RA and experience persistent symptoms despite medication, a comprehensive evaluation of the mucosal triggers, nutritional status, and cardiovascular risk that conventional rheumatology does not routinely assess is warranted.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Rheumatoid Arthritis

At The Lamkin Clinic, rheumatoid arthritis is managed through integrated conventional and functional medicine. Conventional DMARDs and biologics provide disease activity control. Functional medicine provides the gut-joint axis evaluation, microbiome restoration, anti-inflammatory dietary modification, oral health assessment, nutrient optimization, and cardiovascular risk evaluation that conventional rheumatology does not routinely address. The goal is deeper remission, joint preservation, medication minimization, and cardiovascular risk reduction.

Related Conditions

Related Symptoms